NASDAQ:GPCR Structure Therapeutics (GPCR) Stock Price, News & Analysis $21.05 +0.65 (+3.19%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$21.50 +0.45 (+2.14%) As of 03/14/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Structure Therapeutics Stock (NASDAQ:GPCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Structure Therapeutics alerts:Sign Up Key Stats Today's Range$20.27▼$21.4950-Day Range$19.81▼$30.7552-Week Range$19.39▼$62.74Volume801,491 shsAverage Volume831,665 shsMarket Capitalization$1.21 billionP/E RatioN/ADividend YieldN/APrice Target$81.29Consensus RatingBuy Company OverviewStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More… Remove Ads Structure Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreGPCR MarketRank™: Structure Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 738th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingStructure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageStructure Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Structure Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Structure Therapeutics are expected to grow in the coming year, from ($0.82) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Structure Therapeutics is -28.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Structure Therapeutics is -28.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStructure Therapeutics has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Structure Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.70% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Structure Therapeutics has recently increased by 4.69%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStructure Therapeutics does not currently pay a dividend.Dividend GrowthStructure Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.70% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Structure Therapeutics has recently increased by 4.69%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.64 News SentimentStructure Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Structure Therapeutics this week, compared to 5 articles on an average week.Search Interest5 people have searched for GPCR on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Structure Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Structure Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.43% of the stock of Structure Therapeutics is held by insiders.Percentage Held by Institutions91.78% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Structure Therapeutics' insider trading history. Receive GPCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GPCR Stock News HeadlinesStructure Therapeutics (GPCR) to Release Earnings on FridayMarch 12 at 1:58 AM | americanbankingnews.comQ4 Earnings Estimate for GPCR Issued By Leerink PartnrsMarch 7, 2025 | americanbankingnews.comYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.March 15, 2025 | American Alternative (Ad)Q1 Earnings Estimate for GPCR Issued By Leerink PartnrsMarch 5, 2025 | americanbankingnews.comWilliam Blair Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Outperform RecommendationMarch 1, 2025 | msn.comRSI Alert: Structure Therapeutics (GPCR) Now OversoldFebruary 28, 2025 | nasdaq.comStifel Nicolaus Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)February 28, 2025 | markets.businessinsider.comStructure Therapeutics price target lowered to $87 from $91 at Citizens JMPFebruary 28, 2025 | markets.businessinsider.comSee More Headlines GPCR Stock Analysis - Frequently Asked Questions How have GPCR shares performed this year? Structure Therapeutics' stock was trading at $27.12 at the start of the year. Since then, GPCR stock has decreased by 22.4% and is now trading at $21.05. View the best growth stocks for 2025 here. How were Structure Therapeutics' earnings last quarter? Structure Therapeutics Inc. (NASDAQ:GPCR) posted its quarterly earnings data on Thursday, February, 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. When did Structure Therapeutics IPO? Structure Therapeutics (GPCR) raised $150 million in an IPO on Friday, February 3rd 2023. The company issued 10,740,000 shares at a price of $13.00-$15.00 per share. Who are Structure Therapeutics' major shareholders? Top institutional shareholders of Structure Therapeutics include Wellington Management Group LLP (13.60%), FMR LLC (10.62%), Janus Henderson Group PLC (7.26%) and Capital Research Global Investors (6.18%). How do I buy shares of Structure Therapeutics? Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Structure Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Structure Therapeutics investors own include Alamos Gold (AGI), Plug Power (PLUG), KALA BIO (KALA), Ovid Therapeutics (OVID), Comtech Telecommunications (CMTL), Fortress Biotech (FBIO) and Alto Ingredients (ALTO). Company Calendar Last Earnings2/27/2025Today3/15/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GPCR CIK1888886 Webwww.structuretx.com Phone628-229-9277FaxN/AEmployees136Year FoundedN/APrice Target and Rating Average Stock Price Target$81.29 High Stock Price Target$118.00 Low Stock Price Target$50.00 Potential Upside/Downside+286.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-16.37% Return on Assets-15.68% Debt Debt-to-Equity RatioN/A Current Ratio27.63 Quick Ratio27.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.77 per share Price / Book2.15Miscellaneous Outstanding Shares57,343,000Free Float51,861,000Market Cap$1.21 billion OptionableOptionable Beta-2.35 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:GPCR) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.